• Home
  • Browse
    • Current Issue
    • By Issue
    • By Author
    • By Subject
    • Author Index
    • Keyword Index
  • Journal Info
    • About Journal
    • Aims and Scope
    • Editorial Board
    • Publication Ethics
    • Peer Review Process
  • Guide for Authors
  • Submit Manuscript
  • Contact Us
 
  • Login
  • Register
Home Articles List Article Information
  • Save Records
  • |
  • Printable Version
  • |
  • Recommend
  • |
  • How to cite Export to
    RIS EndNote BibTeX APA MLA Harvard Vancouver
  • |
  • Share Share
    CiteULike Mendeley Facebook Google LinkedIn Twitter
Journal of Advanced Biomedical and Pharmaceutical Sciences
arrow Articles in Press
arrow Current Issue
Journal Archive
Volume Volume 8 (2025)
Volume Volume 7 (2024)
Volume Volume 6 (2023)
Issue Issue 4
Issue Issue 3
Issue Issue 2
Issue Issue 1
Volume Volume 5 (2022)
Volume Volume 4 (2021)
Volume Volume 3 (2020)
Volume Volume 2 (2019)
Volume Volume 1 (2018)
Hammad, A., Mohamed M, S., Khalifa, M., El-Daly, M. (2023). Mechanisms of Paclitaxel-induced peripheral neuropathy. Journal of Advanced Biomedical and Pharmaceutical Sciences, 6(1), 25-35. doi: 10.21608/jabps.2022.170238.1172
Asmaa Hammad; Sayed Ahmed Mohamed M; Mohamed Khalifa; Mahmoud El-Daly. "Mechanisms of Paclitaxel-induced peripheral neuropathy". Journal of Advanced Biomedical and Pharmaceutical Sciences, 6, 1, 2023, 25-35. doi: 10.21608/jabps.2022.170238.1172
Hammad, A., Mohamed M, S., Khalifa, M., El-Daly, M. (2023). 'Mechanisms of Paclitaxel-induced peripheral neuropathy', Journal of Advanced Biomedical and Pharmaceutical Sciences, 6(1), pp. 25-35. doi: 10.21608/jabps.2022.170238.1172
Hammad, A., Mohamed M, S., Khalifa, M., El-Daly, M. Mechanisms of Paclitaxel-induced peripheral neuropathy. Journal of Advanced Biomedical and Pharmaceutical Sciences, 2023; 6(1): 25-35. doi: 10.21608/jabps.2022.170238.1172

Mechanisms of Paclitaxel-induced peripheral neuropathy

Article 4, Volume 6, Issue 1, January 2023, Page 25-35  XML PDF (475.87 K)
Document Type: Review Articles
DOI: 10.21608/jabps.2022.170238.1172
View on SCiNiTO View on SCiNiTO
Authors
Asmaa Hammad email 1; Sayed Ahmed Mohamed M2; Mohamed Khalifa3; Mahmoud El-Dalyorcid 4
1Department of pharmacology and toxicology, faculty of pharmacy, Minia university, Egypt
2Pharmacology and Experimental Oncology Unit, National Cancer Institute, Cairo University, Egypt.
3Department of Pharmacology and Toxicology, Faculty of Pharmacy, Minia University, Egypt
4Department of Pharmacology & Toxicology, Faculty of Pharmacy, Minia University, El-Minia 61519, Egypt
Abstract
Peripheral neuropathy is a common adverse effect associated with the use of a group of chemotherapeutic agents including paclitaxel (PTX) which negatively affect the quality of life of cancer survivors. In addition, it is considered as a dose-limiting side effect that hinder completion of appropriate chemotherapy regimen. In spite of 27 years of research in mechanisms of PTX neuropathy, there is no approved therapy for prevention of PTX-induced peripheral neuropathy (PIPN). Thus, there is a continuous need to characterize the possible mechanisms associates with PIPN in order to find appropriate targeted therapy for this clinical problem. In this review, we summarized most of the recent findings of the cellular targets implicated in PIPN.
 
Keywords
Paclitaxel neuropathy; immune reaction; axonal transport; mitochondrial dysfunction
Main Subjects
Pharmacology and Toxicology
Statistics
Article View: 662
PDF Download: 1,164
Home | Glossary | News | Aims and Scope | Sitemap
Top Top

Journal Management System. Designed by NotionWave.